HCPCS Level II · Drugs administered other than oral method
J7513Daclizumab, parenteral, 25 mg
Terminated 12/31/2025
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About J7513
J7513 is an HCPCS Level II code in the J series (drugs administered other than oral method), describing daclizumab, parenteral, 25 mg.
It was added to HCPCS effective 01/01/1999, and its current record took effect 01/01/2026.
It was terminated on 12/31/2025 and can't be billed for later dates of service.
Its Medicare coverage code is "D", meaning special Medicare coverage instructions apply.
Details
- Short description
- Daclizumab, parenteral
- Date added
- 01/01/1999
- Action effective
- 01/01/2026
- Termination date
- 12/31/2025
- BETOS
- O1E
Related J75xx codes
- J7500Azathioprine, oral, 50 mg
- J7501Azathioprine, parenteral, 100 mg
- J7502Cyclosporine, oral, 100 mg
- J7503Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg
- J7504Lymphocyte immune globulin, antithymocyte globulin, equine, parenteral, 250 mg
- J7507Tacrolimus, immediate release, oral, 1 mg
- J7508Tacrolimus, extended release, (astagraf xl), oral, 0.1 mg
- J7509Methylprednisolone oral, per 4 mg
- J7510Prednisolone oral, per 5 mg
- J7511Lymphocyte immune globulin, antithymocyte globulin, rabbit, parenteral, 25 mg
- J7512Prednisone, immediate release or delayed release, oral, 1 mg
- J7515Cyclosporine, oral, 25 mg
Common questions about J7513
Is HCPCS J7513 still valid?
- No. J7513 was terminated on 12/31/2025.
Does Medicare cover J7513?
- Its coverage code is "D": special Medicare coverage instructions apply. Check the local coverage determination for your region.